Related Experiment Video
Updated: Feb 15, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
A novel patient-derived xenograft model for claudin-low triple-negative breast cancer
Margarite D Matossian1, Hope E Burks1, Annie C Bowles2
1Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
Background:
Triple-negative breast cancer (TNBC) subtypes are clinically aggressive and cannot be treated with targeted therapeutics commonly used in other breast cancer subtypes. The claudin-low (CL) molecular subtype of TNBC has high rates of metastases, chemoresistance and recurrence. There exists an urgent need to identify novel therapeutic targets in TNBC; however, existing models utilized in target discovery research are limited. Patient-derived xenograft (PDX) models have emerged as superior models for target discovery experiments because they recapitulate features of patient tumors that are limited by cell-line derived xenograft methods.
Methods:
We utilize immunohistochemistry, qRT-PCR and Western Blot to visualize tumor architecture, cellular composition, genomic and protein expressions of a new CL-TNBC PDX model (TU-BcX-2O0). We utilize tissue decellularization techniques to examine extracellular matrix composition of TU-BcX-2O0.
Results:
Our laboratory successfully established a TNBC PDX tumor, TU-BCX-2O0, which represents a CL-TNBC subtype and maintains this phenotype throughout subsequent passaging. We dissected TU-BCx-2O0 to examine aspects of this complex tumor that can be targeted by developing therapeutics, including the whole and intact breast tumor, specific cell populations within the tumor, and the extracellular matrix.
Conclusions:
Here, we characterize a claudin-low TNBC patient-derived xenograft model that can be utilized for therapeutic research studies.
Insights
Researchers developed a new claudin-low triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) model. This model, TU-BcX-2O0, is crucial for discovering novel therapeutic targets in aggressive TNBC subtypes.
Area of Science:
- Oncology
- Cancer Biology
- Translational Research
Background:
- Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies.
- The claudin-low (CL) subtype of TNBC exhibits high metastasis, chemoresistance, and recurrence rates.
- Existing models for TNBC research are limited, necessitating improved models for therapeutic target discovery.
Purpose of the Study:
- To establish and characterize a novel claudin-low TNBC patient-derived xenograft (PDX) model.
- To assess the utility of this PDX model for preclinical therapeutic research.
Main Methods:
- Immunohistochemistry, qRT-PCR, and Western Blot were used to analyze the established TNBC PDX model (TU-BcX-2O0).
- Tissue decellularization techniques were employed to investigate the extracellular matrix composition of the model.
- Genomic and protein expressions, tumor architecture, and cellular composition were examined.
Main Results:
- A new CL-TNBC PDX model, TU-BcX-2O0, was successfully established and maintained its phenotype through passaging.
- The model was dissected to analyze its components, including the whole tumor, specific cell populations, and extracellular matrix, for potential therapeutic targeting.
- TU-BcX-2O0 recapitulates key features of patient tumors, offering a superior platform for target discovery compared to cell-line derived xenografts.
Conclusions:
- A characterized claudin-low TNBC patient-derived xenograft model (TU-BcX-2O0) has been developed.
- This model serves as a valuable preclinical tool for therapeutic research in TNBC.
- The established PDX model facilitates the investigation of novel therapeutic targets within the complex tumor microenvironment.
More Related Videos
Related Concept Videos
01:06Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
01:23Negative Regulator Molecules
00:58Positive, Negative, and Zero Work
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
01:18Positive and Negative Feedback Loops